1057 results about "Ferroptosis" patented technology

The invention discloses a near-infrared emission aggregation-induced emission organic photo-thermal molecule and a preparation method and application thereof, and belongs to the technical field of biomedicine, and the structure is shown as a formula I: # imgabs0 # (I), wherein R1, R2, R3, R4, R5 and R6 are independently selected from groups containing alkyl chains. The invention also provides a preparation method of the organic photo-thermal molecule and application of the organic photo-thermal molecule in preparation of multifunctional protein nanoparticles with near-infrared aggregation-induced emission. The near-infrared emission aggregation-induced emission organic photo-thermal molecule provided by the invention shows excellent near-infrared imaging effect and photo-thermal capability under laser irradiation, and the obtained near-infrared aggregation-induced emission multifunctional protein nano particle has excellent photo-thermal effect and imaging resolution, has excellent targeting to brain tumor, and has good application prospects in blood brain barrier crossing, brain tumor targeting and brain tumor targeting. And tumor killing, photothermal and ferroptosis combined treatment has practical medical significance, and is expected to be widely applied to the aspects of intelligent drug delivery and nano medical treatment.

The invention discloses a tumor cholesterol metabolism regulation microneedle patch and a preparation method, the microneedle patch comprises a needle tip and a backing which are connected, the needle tip comprises a needle tip body and nanoparticles loaded on the needle tip body, the nanoparticle is a manganese ion-doped organic metal framework, the outer layer of the manganese ion-doped organic metal framework is modified with a targeting agent, cholesterol oxidase and superoxide dismutase are carried on the manganese ion-doped organic metal framework, the targeting agent can target a CD44 receptor, and the organic metal framework can carry drugs. The targeted drug can enter tumor cells in a targeted mode, superoxide dismutase catalyzes superoxide anions overexpressed in the tumor cells to generate H2O2 and O2, O2 needed by catalysis is provided for cholesterol oxidase, cholesterol at the tumor site is consumed by the cholesterol oxidase, accumulation of 7-DHC is reduced, meanwhile H2O2 can be generated, and the cholesterol oxidase can be used for catalyzing the tumor site. H2O2 is catalyzed by manganese ions through a Fenton-like reaction to generate OH to induce tumor cells to generate ferroptosis, so that ferroptosis-immune synergistic treatment is realized.

The invention belongs to the technical field of hydrogel, and particularly relates to animal glue composite hydrogel as well as a preparation method and application thereof. The animal glue composite hydrogel comprises animal glue, polyvinyl alcohol, glycerol and water. The animal glue composite hydrogel provided by the invention not only has rheological and mechanical properties similar to those of natural nucleus pulposus, adapts to the mechanical environment of intervertebral discs, but also has tissue adhesion, can be adhered to soft tissues and avoid leakage, and also can inhibit lipid peroxidation of nucleus pulposus cells in the reactive oxygen species (ROS) environment, reduce cell ferroptosis and promote nucleus pulposus repair.

According to the GPX4 protein degradation agent and the application, the degradation agent serves as molecular glue to induce tumor cell ferroptosis and is different from an existing PROTAC technology, and the molecular glue can induce interaction between E3 ubiquitin ligase and target protein GPX4 and promote ubiquitination of the E3 ubiquitin ligase and the target protein GPX4. Compared with the existing GPX4 degradation agent, the molecular glue has the advantages of small molecular weight, high cell permeability and better druggability. The GPX4 molecular glue disclosed by the invention can be used for effectively degrading GPX4 and has a killing effect on various tumor cell lines. The preparation method is simple in synthesis route and mild in reaction condition, can be used for being developed into a new generation of GPX4 targeting drugs, and has great clinical application value and considerable market potential.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

The invention is applicable to the technical field of biological medicine, and provides a gadolinium-based nano-composite and application thereof in preparation of a medicine for reversing NSCLC radiation resistance, and a preparation method of the gadolinium-based nano-composite comprises the following steps: synthesizing NaYF4: Yb / Er; synthesizing NaYF4: Yb / Er (at) NaGdF4; synthesizing NaYF4: Yb / Er (at) NaGdF4 (at) mSiO2; 3-aminopropyltrimethoxysilane is added into a NaYF4: Yb / Er (at) NaGdF4 (at) mSiO2 aqueous solution, stirring is performed overnight, washing is performed, shSPARC plasmids are added, and a reaction is performed at the room temperature. The gadolinium-based nanocomposite prepared by the invention has both gene intervention and radiation sensitization functions, is good in biocompatibility, and can regulate the ferroptosis sensitivity of radiation-resistant tumors in a targeted manner, improve the ferroptosis inhibition effect, reverse the radiation resistance of resistant cells and improve the radiotherapy effect.

The invention relates to the field of biological medicine, in particular to IMSFs hydrogel, a ferroptosis induction system, a preparation method and application. The IMSFs hydrogel comprises a hydrogel body, and ferroferric oxide nanoparticles and sorafenib are loaded in the hydrogel body in a wrapping manner. The IMSFs hydrogel can be used as an injectable cascade ferroptosis anti-cancer drug. The preparation method of the IMSFs hydrogel comprises the following steps: firstly, preparing a silk fibroin-hyaluronic acid hydrogel body: dissolving silk hydrogel and hyaluronic acid in a lithium bromide solution; bDDE is added into the dissolved solution, and incubation is carried out; then dialyzing and washing with deionized water to obtain a silk fibroin-hyaluronic acid hydrogel body; and then loading the sorafenib nanoparticles and the ferroferric oxide nanoparticles into the silk fibroin-hyaluronic acid hydrogel body. The IMSFs hydrogel disclosed by the invention integrates magnetic thermal response and drug controlled release, and can be injected to a tumor site, so that the treatment effect on TNBC is remarkably improved.

The invention belongs to the technical field of biomedical materials, and particularly relates to a photothermal nano-drug containing a guanidyl structure as well as a preparation method and application of the photothermal nano-drug, and the photothermal nano-drug is CA-COFBT-TG (at) TS obtained by taking COFBT-TG containing guanidyl as a carrier, loading a photothermal agent TS and then modifying a fibrin targeting peptide CA on the surface. The photo-thermal nano-drug is a covalent organic framework material platform, can be enriched at a thrombus part, has excellent photo-thermal conversion performance, can effectively remove thrombus at a focus part, and can improve neuronal death after cerebral arterial thrombosis by inhibiting ferroptosis.

The invention belongs to the technical field of biological medicines, and particularly relates to an iron-based nano material, a preparation method and application of the iron-based nano material in preparation of medicines for treating breast cancer. The iron-based nano material is formed by loading a ferroptosis inducer on a nano carrier; the nano carrier is an iron-based metal organic framework material Fe-MOF (Metal Organic Framework). A product FEH for treating breast cancer is obtained based on coupling of the iron-based nano-material provided by the invention with a targeted drug such as trastuzumab. The FEH provides a new method for developing a nano platform with an antibody function, and realizes a treatment strategy of trastuzumab and ferroptosis combined anti-tumor. As a safe and effective tumor treatment strategy, the EFH has huge clinical transformation potential.

The invention discloses gallium ion-quercetin coordination nanoparticles (GQNPs) as well as a preparation method and application thereof, specifically, quercetin, gallium nitrate hydrate and polyvinylpyrrolidone are respectively dissolved in an absolute methanol solution to prepare a quercetin solution, a gallium nitrate hydrate solution and a polyvinylpyrrolidone solution; secondly, fully mixing the quercetin solution and the polyvinylpyrrolidone solution, dropwise adding the gallium nitrate hydrate solution, and rapidly changing the color of the mixed solution from faint yellow to orange yellow in the dropwise adding process; and finally, dialyzing the orange-yellow mixed solution to remove excessive gallium ions and polyvinylpyrrolidone, thereby finally obtaining the GQNPs. The prepared GQNPs and deferiprone show excellent treatment effects on cell and living body levels, are expected to be applied to treatment of Parkinson's disease through multi-dimensional anti-ferroptosis, do not show obvious toxic and side effects in the embodiment, and are expected to be applied to further preclinical research.

The invention relates to the technical field of nano-drug presentation systems, in particular to a nanoparticle for synergistically promoting hepatoma ferroptosis based on mesoporous manganese dioxide, salazosulfapyridine and a tumor cell biological membrane as well as a preparation method and application of the nanoparticle. The nanoparticle in the scheme comprises mesoporous manganese dioxide which is modified with a tumor cell membrane on the surface and loaded with salazosulfapyridine. According to the technical scheme, the nanoparticles can effectively induce hepatoma cell ferroptosis through a multi-target strategy. The salazosulfapyridine and the mesoporous manganese dioxide have a synergistic effect to enhance the ferroptosis effect; the tumor cell biological membrane has homologous targeting property, so that the accumulation capacity of the nanoparticles in liver cancer tissues is remarkably improved; the nanoparticle provided by the invention not only can be used for treatment, but also can monitor the change in the treatment process in real time. According to the technical scheme, the technical problem that a nano-drug presentation system for effectively inducing ferroptosis aiming at multiple target spots is lacked in the prior art can be solved, and the technical scheme has important significance in improving the survival rate and the life quality of liver cancer patients.

The invention discloses a ferroptosis inhibitor and application of the ferroptosis inhibitor in radiation pneumonitis drugs, and relates to the technical field of biological medicines. The specific preparation method comprises the following steps: adding the ferroptosis inhibitor and the auxiliary agent into the solvent, and dissolving to obtain the ferroptosis inhibitor composition; wherein the ferroptosis inhibitor is isoorientin; the auxiliary agent is a glucosamine derivative; the solvent is a serum-free DMEM culture medium. The ferroptosis inhibitor composition prepared by the method provided by the invention can effectively reduce the rise of active oxygen, ferrous ions and malondialdehyde levels of human pulmonary epithelial cells BEAS-2b and mouse pulmonary epithelial cells MLE-12 caused by irradiation, restore cell mitochondrial membrane potential enrichment and inhibit the expression of various inflammatory factors in irradiated cells; therefore, the process of radiation pneumonitis is remarkably improved, and a new medication strategy is provided for research on radiation pneumonitis drugs.

The invention belongs to the technical field of medicinal chemistry, and discloses a preparation method and application of a benzofuran [2, 3-b] pyridine derivative of a targeted nuclear receptor co-activator 4 (NCOA4). The derivative has a structural general formula as shown in the following formula (I), wherein R1, R2 and R3 substituent groups can be combined at will. The compounds are combined with NCOA4 to interfere the cell iron autophagy process and effectively inhibit the ferroptosis of various cells induced by RSL3 or Erastin. Particularly, the binding affinity of the compound 4k and NCOA4 is optimal (Kd is equal to 0.78 mu M), and the compound 4k has remarkable ferroptosis inhibition activity and can be used for research and development of medicines for ferroptosis-related diseases. # imgabs0 #

The invention relates to the technical field of medical chemistry, in particular to a bridge oxygen site regulatively modified rhodamine anti-cancer fluorescent compound as well as a preparation method and application thereof. The invention develops the rhodamine anti-cancer fluorescent compound of which the meso site is functionalized by tetraarylethene and the bridge oxygen site can be regulated and modified, the fluorescent compound has adjustable red light-near infrared fluorescence emission and excellent fluorescence quantum yield, and the quantum yield can be as high as 99%; the fluorescent compound specifically targets mitochondria, and mainly inhibits growth of tumor cells by inducing para-apoptosis; under irradiation of 655 nm near-infrared laser, ferroptosis is further triggered, efficient treatment of tumor cells is achieved through chemical-photodynamic synergistic effect, and a new treatment thought is provided for overcoming tumor drug resistance.

The invention discloses a preparation method and application of a novel hybrid extracellular vesicle. According to the invention, vesicles derived from endothelial cells and neutrophil cells are combined with deferoxamine, and a biological mixed nano vesicle platform (DFO (HEVS)) is developed to solve the problem of diabetes wound healing. According to the dual-targeting system, DFO is accurately delivered to a wound part by utilizing CXCR4 mediated endothelial cell homing and beta2 integrin dependent inflammation tropism, DFO (at) HEVs activates and recovers vascular regeneration through HIF-1alpha / VEGF, ferroptosis is inhibited through Nrf2 / GPX4 signal transduction, macrophages are reprogrammed into a repair promoting M2 phenotype, and oxidative stress-inflammation-ferroptosis circulation is effectively broken.

The invention relates to the technical field of medicines, and discloses application of D-mannose in prevention and treatment of androgenetic alopecia. In the prior art, D-mannose can be a potential strategy for treating ferroptosis related diseases, can also be a non-prescription medicine supplement with high safety, and is used for treating neuritis diseases such as multiple sclerosis. The androgenic alopecia mouse model is constructed by utilizing dihydrotestosterone induction, the model mouse is subjected to mannose intervention, and the result shows that application of mannose can promote mouse hair growth, increase cortex thickness, promote hair regeneration and melanogenesis and effectively resist alopecia caused by dihydrotestosterone. The invention provides a new effect of mannose in prevention and treatment of androgenetic alopecia, and also provides a new strategy for prevention and treatment of androgenetic alopecia.

[Problem] To provide a novel ferroptosis-inducing drug, and in particular, to provide a ferroptosis induction promoter that can effectively promote the induction of ferroptosis even in a cell having ferroptosis resistance even in a ferroptosis-inducing environment (for example, cancer cells and senescent cells). [Solution] Provided is a ferroptosis induction promoter comprising a drug that can reduce lysosomal pH.

The invention discloses application of indobufen in preparation of a medicine for preventing and treating diseases induced by excessive ferroptosis, and particularly relates to the technical field of medicines. The invention relates to an application of indobufen in preparation of drugs for preventing and treating diseases induced by excessive ferroptosis by inhibiting ferroptosis. The indobufen is a ferroptosis inhibitor. The invention provides a new application of indobufen alone or in combination with other drugs in promoting wound healing. Cell and animal level experiments prove that the indobufen can inhibit the local ferroptosis level of the wound surface, so that the wound surface healing is obviously accelerated, and the indobufen has a good clinical application prospect.

The invention belongs to the technical field of medicinal chemistry, and discloses a preparation method and application of a 5-aryl substituted 1, 2, 4-triazole iron death inhibitor derivative. The derivative has a structural general formula as shown in the following formula (I), wherein Ar1 and Ar2 substituent groups can be combined at will. The compound can be used for efficiently removing cell lipid peroxides and effectively inhibiting ferroptosis processes of various cells. Particularly, the compound SN26 has optimal ferroptosis inhibitory activity (786-O cell line, EC50 = 62nM), and can effectively improve acute liver injury of mice caused by concanavalin by inhibiting ferroptosis. The research is expected to be used for developing ferroptosis inhibitors and research and development of small molecule drugs for related diseases. # imgabs0 #

The invention relates to a nano assembly for self-synergistically enhancing ferroptosis as well as a preparation method and application of the nano assembly, and belongs to the technical field of pharmaceutical preparation combined treatment of new auxiliary materials and new dosage forms. The invention firstly provides a functional conjugate linker capable of automatically generating ROS, the functional conjugate linker comprises artesunate-ferrocene or dihydroartemisinin-ferrocene, and the structural formulas of the functional conjugate linker and the artesunate-ferrocene or dihydroartemisinin-ferrocene are respectively shown as a and b. According to the present invention, the ROS self-generating functional conjugate linker and the ferroptosis inducer are co-assembled to form the nanometer assembly, such that the ROS level in the tumor cells can be effectively and synergistically improved by the ROS self-generating functional conjugate linker and the ferroptosis inducer so as to cause the tumor cell lipid peroxidation storm, and the ferroptosis induction effect can be significantly improved. The co-assembled nano preparation provided by the invention provides a new strategy and more choices for developing the delivery of drugs, and meets the urgent requirements of efficient and diversified ferroptosis-based cancer treatment strategies on preparations in clinic. # imgabs0 #

The invention relates to the technical field of medicines, and provides a synergetic nano chemotherapy preparation for treating pancreatic cancer and a preparation method of the synergetic nano chemotherapy preparation. According to the synergistic nano chemotherapy preparation, an RGD peptide modified lipid-mesoporous silica nano delivery system is used for simultaneously encapsulating a ferroptosis inducer Erastatin and a chemotherapy drug gemcitabine hydrochloride hcGEM. The nano synergistic treatment system not only can actively deliver the drug to the pancreatic tumor tissue with high expression of the integrin receptor in a targeted manner through the surface-modified RGD peptide, but also can realize drug synergistic treatment, and improves the killing effect of the drug on pancreatic cancer cells while reducing the toxic and side effects.

The invention discloses a multifunctional nano delivery system based on targeted ferritin as well as a preparation method and application of the multifunctional nano delivery system. According to the system, traditional Chinese medicine active ingredients, namely neogambogic acid GNA, a photosensitizer Ce6 and ferritin targeting peptide HKN15 are integrated through a self-assembly technology, a synergistic treatment system integrating photodynamic therapy PDT and ferroptosis induction is constructed, and the treatment effect on non-small cell lung cancer NSCLC can be remarkably enhanced. According to the nano delivery system, precise targeting of a tumor site is achieved through the ferritin targeting peptide HKN15, and a double anti-tumor mechanism is formed by utilizing the photodynamic effect of the photosensitizer Ce6 and the ferroptosis induction effect of GNA. The preparation process is based on a molecular self-assembly principle, and has the advantages of high tumor accumulation efficiency, low system toxicity, remarkable tumor inhibition effect and the like, and an innovative solution is provided for precise treatment of the non-small cell lung cancer.

The present invention relates to a compound of Formula 1, a preparation method thereof, a pharmaceutical composition comprising the same as an active ingredient, and a use thereof. The compound of Formula 1 according to the present invention can exhibit cell necrosis and ferroptosis inhibitory efficacy in various cells such as heart, kidney, nerve, retina, liver, or lung cells, and accordingly, can be usefully used for prevention or treatment of cell necrosis or ferroptosis-related diseases.

The invention discloses application of a therapeutic target to preparation of a drug for resisting cancer cell cis-platinum resistance. The therapeutic target is NPR1; the NPR1 is used for inhibiting mitochondrial autophagy-dependent ferroptosis by inhibiting the ubiquitination degradation level of PARL. The invention discloses a therapeutic target NPR1 and an NPR1-MARCH8-PARL axis, expression of PARL can be down-regulated by blocking or inhibiting the NPR1 or NPR1-MARCH8-PARL axis, and a mitochondrial autophagy-dependent ferroptosis process can be recovered, so that drug resistance of gastric cancer cells is inhibited, and a new method is further provided for preparing drugs for resisting cisplatin drug resistance of the gastric cancer cells.

The invention discloses an AuAgPt ternary alloy nano-framework, a preparation method thereof and application of the AuAgPt ternary alloy nano-framework in anti-tumor preparations, and belongs to the field of biomedical nano-materials. The AuAgPt ternary alloy nano frame is a hollow octahedral nano frame formed by 12 AuAgPt ternary alloy edges, and the nano frame has plasmon photothermal conversion performance, catalase activity and peroxidase-like activity, and can be used for preparing the nano frame. The aptamer has the characteristics that the aptamer can form a covalent bond with glutathione (GSH), the aptamer with the framework surface capable of being modified and specifically bound with tumor cells is used for tumor targeted delivery and the like, the aptamer can be bound in a targeted manner and internalized into the tumor cells, and after near-infrared laser irradiation, the cell temperature can be increased to 42 DEG C, reactive oxygen species (ROS) can be generated, GSH can be consumed, and the tumor targeting effect is achieved. In addition, the content change of small molecule metabolites in cells can be driven through a low-temperature photothermal effect, the metabolic state is disturbed, the redox balance in the cells is destroyed, the tumor cells are induced to generate ferroptosis and apoptosis, and the low-temperature photothermal treatment of tumors is realized.

The invention belongs to the technical field of triple negative breast cancer, and particularly relates to application of a polypeptide capable of specifically blocking phosphorylation of metabolic enzyme PSAT1S337 and functional remodeling of PSAT1 in preparation of a triple negative breast cancer treatment product. The phosphorylated polypeptide targeting PSAT1S337 is designed, and it is found that the polypeptide obviously inhibits growth of triple negative breast cancer tumors and can improve the curative effect of anti-PD-1 immunotherapy at the animal level. Meanwhile, the invention further provides application of the reagent for detecting the phosphorylation level of the PSAT1S337 and / or the hydroxylation level of the GPX4P159 in preparation of products for diagnosing and prognosing the triple negative breast cancer. The invention discloses a molecular mechanism of functional remodeling of the serine metabolic enzyme PSAT1 in occurrence and development of cell ferroptosis and triple negative breast cancer, and provides a new thought and an effective scheme for research and development of anti-tumor drugs for targeted serine metabolism reprogramming and early diagnosis of tumors.

The invention relates to a pharmaceutical composition for treating acute myelogenous leukemia. The pharmaceutical composition comprises lonidamine and a GPX4 inhibitor. The invention also relates to application of the pharmaceutical composition in preparation of drugs for resisting acute myelogenous leukemia cells. Aiming at an oxidation-antioxidation defense system of AML tumor cells, lonidamine and the GPX4 inhibitor are creatively combined for use, the inhibition rate of lonidamine and the GPX4 inhibitor on the AML cells is remarkably higher than that of independent medication, and the combination of lonidamine and the GPX4 inhibitor can synergistically inhibit the activity of the AML cells, induce mitochondria damage of the AML cells and promote ferroptosis of the AML cells, so that the purpose of treating the AML is achieved.

The invention relates to a training method of a respiratory tract infection disease progress and prognosis prediction model. The training method comprises the following steps: extracting mRNA from peripheral blood of a target patient, and carrying out transcriptome sequencing to obtain a sequencing result; based on the ferroptosis related gene set, comparing ferroptosis score differences of two groups of patients with community-acquired pneumonia and sepsis, and screening corresponding ferroptosis related genes with statistical significance from a sequencing result; screening out genes meeting preset conditions from the ferroptosis related genes based on LASSO regression; and establishing an RTI clinical outcome prediction model through logistic regression by taking whether the patient is sepsis or not as an outcome dichotomy variable and taking the screened gene expression quantity as a prediction variable. According to the invention, after the prediction model is subjected to machine learning screening such as LASSO and the like, the core feature with the highest prediction value is reserved, so that the risk of over-fitting of the model on training data is reduced.

The invention discloses a microneedle patch loaded with a sorafenib and copper-doped Prussian blue nano material and application of the microneedle patch in in-situ triple-negative breast cancer treatment. The sorafenib and the copper-doped Prussian blue nano material are loaded in a needle body of the microneedle patch. The microneedle patch can accurately deliver nanoparticles and sorafenib to tumor tissues, the chemical kinetics effect is enhanced through an efficient and mild photothermal therapy, the ferroptosis of triple negative breast cancer cells is enhanced through ferroptosis induced by the nanoparticles and sorafenib in cooperation with drugs, then cell death is induced, and the curative effect is improved. And a brand-new and promising treatment method is provided for in-situ triple-negative breast cancer treatment.

The invention relates to the technical field of biomedicine, in particular to a mouse intrahepatic bile duct cancer cell strain and a construction method and application thereof, the cell strain is named as mouse intrahepatic bile duct cancer cell strain KP-ICC and preserved in China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC NO: C202574; the cell strain is derived from a KrasG12D / Tp53flox / flox C57BL / 6J mouse, a spontaneous tumor model is constructed through high-pressure hydrodynamic tail vein injection of pT3-Cre and a sleep beauty transposase plasmid, and the spontaneous tumor model is obtained through in-vitro culture, passage, monoclonal screening and tumorigenicity verification. The KP-ICC cell strain naturally has chemotherapy-immune combined treatment drug resistance and ferroptosis resistance characteristics, and can be widely applied to the fields of intrahepatic cholangiocarcinoma drug resistance mechanism research, drug resistance reversing, combined treatment drug development, drug resistance animal model establishment and the like.